FDA Seeks Schedule I Status for ‘Legal Morphine’
The FDA is recommending that 7-hydroxymitragynine (7-OH), a synthetic, concentrated substance derived from kratom leaves, be classified as…
FDA Panel Casts Doubt on Safety of SSRI Use in Pregnancy
On Monday, July 21, a 10-member panel headed by Marty Makary, MD, MPH, commissioner of the FDA convened…
FDA Panel Rejects Combo Drug for PTSD
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti,…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…